<DOC>
	<DOCNO>NCT00631202</DOCNO>
	<brief_summary>Friedreich 's ataxia rare genetic disorder characterize severe neurological disability cardiomyopathy . Friedreich 's ataxia consequence frataxin deficiency . Although several drug propose , available treatment . It recently demonstrate erythropoietin increase intracellular level frataxin in-vitro model . The present project aim test possible therapeutic approach erythropoietin , already available commercialize drug . The investigator perform in-vitro in-vivo test , order ass efficacy safety patient . The result useful plan clinical trial .</brief_summary>
	<brief_title>Efficacy Epoetin Alfa Patients With Friedreich 's Ataxia</brief_title>
	<detailed_description>Friedreich ataxia ( FRDA ) inherit recessive disorder characterize progressive neurological disability . FRDA consequence frataxin deficiency . Although several drug propose FRDA , available treatment . Recently show recombinant human erythropoietin ( rhu-EPO ) administration increase frataxin expression culture human lymphocyte FRDA patient . It therefore primary importance test extensively rhu-EPO 's ability increase frataxin level in-vitro in-vivo . In addition rhu-EPO already available commercialized drug approve treatment anaemia associate chronic renal disease , heart failure cancer . Towards overall purpose , perform acute clinical trial FRDA patient rhu-EPO assess effect in-vivo frataxin expression . In addition , rhu-EPO 's safety FRDA patient base laboratory parameter neurological index test . The result useful gain new insight role rhu-EPO FRDA , future , may useful plan clinical trial .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Molecular diagnosis FA base homozygous GAA expansion within FRDA triplet repeat sequence pathological range . Age &gt; 18 , &lt; 50 year Failure meet one inclusion criterion Patients treatment Idebenone Wheelchair bound patient Significant renal , hepatic haematological disease Positive history arterial venous thrombosis Acute disease might interfere study Positive history arterial hypertension Present program pregnancy Known hypersensitivity study drug Other unacceptable concomitant medication ( particular agent think neuroprotective potential tocopherol , amantadine , memantine , free radical scavenger ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>FRDA</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Epoetin alfa</keyword>
</DOC>